CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive r...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238543/ https://www.ncbi.nlm.nih.gov/pubmed/37268691 http://dx.doi.org/10.1038/s41698-023-00404-w |
_version_ | 1785053317521473536 |
---|---|
author | Song, Bolin Yang, Kailin Viswanathan, Vidya Sankar Wang, Xiangxue Lee, Jonathan Stock, Sarah Fu, Pingfu Lu, Cheng Koyfman, Shlomo Lewis, James S. Madabhushi, Anant |
author_facet | Song, Bolin Yang, Kailin Viswanathan, Vidya Sankar Wang, Xiangxue Lee, Jonathan Stock, Sarah Fu, Pingfu Lu, Cheng Koyfman, Shlomo Lewis, James S. Madabhushi, Anant |
author_sort | Song, Bolin |
collection | PubMed |
description | Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D(1)–D(3). The prognostic performance of pRiS was evaluated on two test sets (D(2), n = 162; D(3), n = 269) using concordance index. Patients from D(2) and D(3) who received either radiotherapy alone or chemoradiation were used to validate pRiS as predictive of added benefit of chemotherapy. Seven features were selected to construct pRiS, which was found to be prognostic of overall survival (OS) on univariate analysis in D(2) (hazard ratio [HR] = 2.14, 95% confidence interval [CI], 1.1–4.16, p = 0.02) and D(3) (HR = 2.74, 95% CI, 1.34–5.62, p = 0.006). Chemotherapy was associated with improved OS for high-pRiS patients in D(2) (radiation vs chemoradiation, HR = 4.47, 95% CI, 1.73–11.6, p = 0.002) and D(3) (radiation vs chemoradiation, HR = 2.99, 95% CI, 1.04–8.63, p = 0.04). In contrast, chemotherapy did not improve OS for low-pRiS patients, which indicates these patients did not derive additional benefit from chemotherapy and could be considered for treatment de-escalation. The proposed radiomic signature was prognostic of patient survival and informed benefit from chemotherapy for stage I and II HPV-associated OPSCC patients. |
format | Online Article Text |
id | pubmed-10238543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102385432023-06-04 CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma Song, Bolin Yang, Kailin Viswanathan, Vidya Sankar Wang, Xiangxue Lee, Jonathan Stock, Sarah Fu, Pingfu Lu, Cheng Koyfman, Shlomo Lewis, James S. Madabhushi, Anant NPJ Precis Oncol Article Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D(1)–D(3). The prognostic performance of pRiS was evaluated on two test sets (D(2), n = 162; D(3), n = 269) using concordance index. Patients from D(2) and D(3) who received either radiotherapy alone or chemoradiation were used to validate pRiS as predictive of added benefit of chemotherapy. Seven features were selected to construct pRiS, which was found to be prognostic of overall survival (OS) on univariate analysis in D(2) (hazard ratio [HR] = 2.14, 95% confidence interval [CI], 1.1–4.16, p = 0.02) and D(3) (HR = 2.74, 95% CI, 1.34–5.62, p = 0.006). Chemotherapy was associated with improved OS for high-pRiS patients in D(2) (radiation vs chemoradiation, HR = 4.47, 95% CI, 1.73–11.6, p = 0.002) and D(3) (radiation vs chemoradiation, HR = 2.99, 95% CI, 1.04–8.63, p = 0.04). In contrast, chemotherapy did not improve OS for low-pRiS patients, which indicates these patients did not derive additional benefit from chemotherapy and could be considered for treatment de-escalation. The proposed radiomic signature was prognostic of patient survival and informed benefit from chemotherapy for stage I and II HPV-associated OPSCC patients. Nature Publishing Group UK 2023-06-02 /pmc/articles/PMC10238543/ /pubmed/37268691 http://dx.doi.org/10.1038/s41698-023-00404-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Song, Bolin Yang, Kailin Viswanathan, Vidya Sankar Wang, Xiangxue Lee, Jonathan Stock, Sarah Fu, Pingfu Lu, Cheng Koyfman, Shlomo Lewis, James S. Madabhushi, Anant CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma |
title | CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma |
title_full | CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma |
title_fullStr | CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma |
title_full_unstemmed | CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma |
title_short | CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma |
title_sort | ct radiomic signature predicts survival and chemotherapy benefit in stage i and ii hpv-associated oropharyngeal carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238543/ https://www.ncbi.nlm.nih.gov/pubmed/37268691 http://dx.doi.org/10.1038/s41698-023-00404-w |
work_keys_str_mv | AT songbolin ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT yangkailin ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT viswanathanvidyasankar ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT wangxiangxue ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT leejonathan ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT stocksarah ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT fupingfu ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT lucheng ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT koyfmanshlomo ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT lewisjamess ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma AT madabhushianant ctradiomicsignaturepredictssurvivalandchemotherapybenefitinstageiandiihpvassociatedoropharyngealcarcinoma |